Key clinical point: Tucatinib is being hailed as a major therapeutic advance for women with heavily pretreated HER2-positive metastatic breast cancer.
Major finding: The 2-year estimated overall survival was 45% in patients on tucatinib and 27% with placebo.
Study details: This pivotal double-blind trial included 612 women with heavily pretreated HER2-positive metastatic breast cancer who were randomized two-to-one to tucatinib or placebo in combination with trastuzumab and capecitabine.
Disclosures: The presenter reported receiving institutional research support from and serving as a consultant to Seattle Genetics, sponsor of the HER2CLIMB trial.
Murthy RK. SABCS 2019. Abstract GS1-01.